Anti-vascular endothelial growth factor therapy in the era of personalized medicine Luis R. FélizApostolia M. Tsimberidou Review Article 06 March 2013 Pages: 1 - 12
Metronomic chemotherapy for cancer treatment: a decade of clinical studies Adriana RomitiM. Christina CoxPaolo Marchetti Review Article 09 March 2013 Pages: 13 - 33
Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells Min ShiBingxiang LouJun Zhang Original Article 28 May 2013 Pages: 35 - 44
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer S. AgelakiE. KontopodisV. Georgoulias Original Article 21 April 2013 Pages: 45 - 51
The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases Anthony El-KhoueiryJames A. PoseyEric Masson Original Article 30 May 2013 Pages: 53 - 64
Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study Sandrine Lavau-DenesP. LacroixN. Tubiana-Mathieu Original Article 01 May 2013 Pages: 65 - 73
Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors R. SalazarH. Cortés-FunesL. Paz-Ares Original Article 05 May 2013 Pages: 75 - 83
A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors Syma IqbalHeinz-Josef LenzEdward M. Newman Original Article 28 May 2013 Pages: 85 - 91
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model Rachel GrossmanBetty TylerHenry Brem Original Article 07 May 2013 Pages: 93 - 100
A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma Lisa N. AbaidJohn P. MichaBram H. Goldstein Original Article 10 May 2013 Pages: 101 - 107
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer Ji-Won KimJee Hyun KimIn Ae Park Original Article 15 May 2013 Pages: 109 - 115
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination Lucio TentoriAlessia MuziGrazia Graziani Original Article 01 May 2013 Pages: 117 - 125
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues Krupa J. PatelOlivier TrédanIan F. Tannock Original Article 17 May 2013 Pages: 127 - 138
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer Christopher M. StephensonRobert D. LevinChristopher G. Lis Original Article Open access 14 May 2013 Pages: 139 - 146
miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1 Jie WangKe SaiZhong-ping Chen Original Article 05 May 2013 Pages: 147 - 158
ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy Sara De DossoElena ZanellatoMilo Frattini Original Article 05 May 2013 Pages: 159 - 165
Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors Hoai-Thu ThaiChristine Veyrat-FolletEmmanuelle Comets Original Article 15 May 2013 Pages: 167 - 180
Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry T.-H. LinK. HuY. Wang Original Article 17 May 2013 Pages: 181 - 188
PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells Atish PatelAmit K. TiwariZhe-Sheng Chen Original Article 15 May 2013 Pages: 189 - 199
Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience Jae-Cheol JoMyoung Joo KangSung-Bae Kim Original Article 14 May 2013 Pages: 201 - 207
Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography Gakuji OsawaKazuhiko YoshimatsuYoshihiko Naritaka Original Article 14 May 2013 Pages: 209 - 215
Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer Katsushi TakebayashiEiji MekataTohru Tani Original Article 01 June 2013 Pages: 217 - 222
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis Jun Ho JiSe Hoon ParkYoung Suk Park Original Article 21 May 2013 Pages: 223 - 230
Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma Peter L. BonateA. Benjamin Suttle Original Article 29 May 2013 Pages: 231 - 240
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies T. H. HanR. ChenA. Engert Original Article 30 May 2013 Pages: 241 - 249
Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells Huaping LiuMetin KurtogluTheodore J. Lampidis Original Article 23 May 2013 Pages: 251 - 262
A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder Zeynep ErogluJohn P. Fruehauf Clinical Trial Report 01 May 2013 Pages: 263 - 267
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma Satoshi NodaMakoto ShioyaTomohiro Terada Short Communication 15 May 2013 Pages: 269 - 272
Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of view Maria Isabel Mas-FusterAmelia Ramon-LopezRicardo Nalda-Molina Letter to the Editor 05 June 2013 Pages: 273 - 274
Erratum to: Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy Gangjun DuYiming YangHouyun Zhang Erratum 17 May 2013 Pages: 275 - 275